Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

April 26 2018 Women and girls of childbearing potential must no longer take valproate medicines...

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

April 23 2018 Buprenorphine has been found to have lower rates of overdose death than methadone...

Class of diabetes drug linked to increased risk of irritable bowel disease

Class of diabetes drug linked to increased risk of irritable bowel disease

March 29 2018 A study has shown that dipeptidylpeptidase-4 inhibitors may increase the risk of...

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

March 29 2018 Mefloquine is safe to use for malaria prevention during pregnancy, a Cochrane...

  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:08
  • Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Thursday, 26 April 2018 11:48
  • Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Monday, 23 April 2018 16:48
  • Class of diabetes drug linked to increased risk of irritable bowel disease

    Class of diabetes drug linked to increased risk of irritable bowel disease

    Thursday, 29 March 2018 11:27
  • Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Thursday, 29 March 2018 11:21

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageFebruary 9 2018

The medicines regulator has issued a Drug Safety Update relating to mycophenolate mofetil and its active metabolite mycophenolic acid, used to prevent transplant rejection. 

The compounds are teratogenic and genotoxic, but clinical evidence so far does not indicate that there is an increased risk of malformations or miscarriage in pregnancies where the father was taking mycophenolate medicines.

However, the MHRA is advising that “there is insufficient evidence to rule out any risk.” As such, it says that “as a precautionary measure for male patients, it is now recommended that either the patient or their female partner use reliable contraception during treatment with mycophenolate medicines and for at least 90 days after stopping.”

The DSU points out that “mycophenolate medicines remain contraindicated in women of childbearing potential who are not using reliable contraception and in pregnant women unless there are no suitable alternatives to prevent transplant rejection.”

In addition, “female patients of childbearing potential must use at least one reliable form of contraception before and during treatment and for six weeks after stopping mycophenolate medicines; two forms of contraception are preferred.”

Links:
MHRA DSU on mycophenolate mofetil, mycophenolic acid        

Clinical News

May 22 2018 A “bespoke, fully funded independent prescribing course for community pharmacists in NHS Scotland” has been announced by Community Pharmacy Scotland.
May 21 2018  NHS England and Capita’s handling of primary care support services has been criticised in an official report. The National Audit Office has published a review saying that “NHS England and...